沙利度胺片致β地中海贫血患者继发性闭经1例分析

doi:10.19803/j.1672-8629.20240468

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (10): 1181-1183.
DOI: 10.19803/j.1672-8629.20240468

沙利度胺片致β地中海贫血患者继发性闭经1例分析

尹春燕¹, 孔文强¹, 杨焜^2,*

¹自贡市第一人民医院药剂科, 四川自贡 643000;
²自贡市第一人民医院血液科, 四川自贡 643000

收稿日期:2024-07-05 出版日期:2024-10-15 发布日期:2024-10-14
通讯作者: ^*杨焜,男,硕士,医师,血液病。E-mail: 1759874951@qq.com
作者简介:尹春燕,女,本科,主管药师,药剂学。

One case of secondary amenorrhea caused by thalidomide tablets in a β-thalassemia patient

YIN Chunyan¹, KONG Wenqiang¹, YANG Kun^2,*

¹Department of Pharmacy, Zigong First People's Hospital, Zigong Sichuan 643000, China;
²Department of Hematology, Zigong First People's Hospital, Zigong Sichuan 643000, China

Received:2024-07-05 Online:2024-10-15 Published:2024-10-14

摘要/Abstract

摘要： 目的探讨沙利度胺导致β地中海贫血患者继发性闭经的临床特征及发病机制。方法分析1例β地中海贫血患者接受沙利度胺片治疗致继发性闭经病例,结合相关文献,讨论临床表现及发生机制。结果患者在沙利度胺治疗5个月后出现闭经,停用4个月后,月经再次出现,激素恢复正常水平,考虑该闭经不良反应很可能为沙利度胺引起。结论沙利度胺可以导致高促性腺激素闭经,在治疗期间需警惕其发生的可能。

关键词: 沙利度胺, 药品不良反应, 继发性闭经, 月经, 贫血, 地中海贫血

Abstract: Objective To explore the clinical characteristics and mechanism of secondary amenorrhea caused by thalidomide in a β-thalassemia patient. Methods Secondary amenorrhea caused by thalidomide in a β-thalassemia patient was analyzed, while the manifestations and pathogenesis were summarized based on literature review. Results The patient developed amenorrhea after 5 months of thalidomide treatment. Four months later, spontaneous menses returned and her hormonal profile returned to normal. The adverse reaction was believed to have been caused by thalidomide. Conclusion Thalidomide can cause hypergonadotropin amenorrhea, so clinicians should be alert to the risk during treatment.

Key words: thalidomide, adverse drug reaction, secondary amenorrhea, menstruation, anemia, thalassemia

中图分类号:

R973
R994.11

尹春燕, 孔文强, 杨焜. 沙利度胺片致β地中海贫血患者继发性闭经1例分析[J]. 中国药物警戒, 2024, 21(10): 1181-1183.

YIN Chunyan, KONG Wenqiang, YANG Kun. One case of secondary amenorrhea caused by thalidomide tablets in a β-thalassemia patient[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1181-1183.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240468

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I10/1181

参考文献

[1] AMARE GG, MEHARIE BG, BELAYNEH YM.A drug repositioning success: the repositioned therapeutic applications and mechanisms of action of thalidomide[J]. Journal of Oncology Pharmacy Practice, 2021, 27(3): 673-678.
[2] VARGESSON N, HOOPER G, LAM SW.Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations[J]. The Journal of Hand Surgery, 2023, 48E(8): 699-709.
[3] ZHANG C, YU Z, GAO S, et al.Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study[J]. Pediatric Rheumatology Online Journal, 2023, 21(1): 124.
[4] DSOUZA NN, ALAMPADY V, BABY K, et al.Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis[J]. Inflammopharmacology, 2023, 31(3): 1167-1182.
[5] EATMANN AI, HAMOUDA E, HAMOUDA H, et al.Potential use of thalidomide in glioblastoma treatment: an updated brief overview[J]. Metabolites, 2023, 13(4): 543.
[6] FOONG WC, LOH CK, HO JJ, et al. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias[J]. The Cochrane Database of Systematic Reviews, 2023, 1: CD013767.
[7] YANG K, LIU X, PENG W, et al.Effects of Thalidomide on erythropoiesis and iron homeostasis in transfusion-dependent beta-thalassemia[J]. Mediterranean Journal of Hematology and Infectious Diseases, 2024, 16: e2024001.
[8] CHEN JM, ZHU WJ, LIU J, et al.Safety and efficacy of thalidomide in patients with transfusion-dependent beta-thalassemia: a randomized clinical trial[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 405.
[9] YANG K, WU Y, ZHOU Y, et al.Thalidomide for patients with beta-thalassemia: a multicenter experience[J]. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12: e2020021.
[10] JIAN X, LIU X, PENG W, et al.Long-term efficacy and safety of thalidomide treatment in children with beta-thalassemia major[J]. Pediatric Blood Cancer, 2023, 70(9): e30391.
[11] ALI Z, ISMAIL M, REHMAN IU, et al.Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent beta-thalassemia: results from Thal-Thalido study[J]. Scientific Reports, 2023, 13(1): 13592
[12] LI X, HU S, LIU Y, et al.Efficacy of thalidomide treatment in children with transfusion dependent beta-thalassemia: a retrospective clinical study[J]. Frontiers in Pharmacology, 2021, 12: 722502.
[13] PULIDO-PEREZ A, LAZARO-OCHAITA P, SUAREZ-FERNANDEZ R.Amenorrhea during thalidomide treatment: an unusual cause of ovarian failure?[J]. Medicina Clinica, 2017, 149(3): 135-136.
[14] ORDI J, CORTES F, MARTINEZ N, et al.Thalidomide induces amenorrhea in patients with lupus disease[J]. Arthritis & Rheumatology, 1998, 41(12): 2273-2275.
[15] LI JB, CHI Q, LIU PC, et al.Evaluation of reproductive system safety of thalidomide in 214 women of childbearing age with rheumatic diseases[J]. Chinese Journal of New Drugs(中国新药杂志), 2023, 32(22): 2270-2274.
[16] SINGHA A, MUKHOPADHYAY P, GHOSH S. Thalidomide-induced primary amenorrhea in a patient with hbe/beta-thalassemia[J]. JCEM Case Reports, 2023, 1(3): luad057.
[17] YU Y, YANG K.Secondary amenorrhea in a beta-thalassemia major patient treated with thalidomide[J]. Pediatric Blood Cancer, 2024, 71(6): e30982.
[18] SILVA JRV, LIMA FEO, SOUZA ALP, et al.Interleukin-1beta and TNF-alpha systems in ovarian follicles and their roles during follicular development, oocyte maturation and ovulation[J]. Zygote, 2020, 28(4): 1-8.
[19] MEIROW D, LEWIS H, NUGENT D, et al.Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool[J]. Human Reproduction, 1999, 14(7): 1903-1907.
[20] RONESS H, KALICH-PHILOSOPH L, MEIROW D.Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents[J]. Human Reproduction Update, 2014, 20(5): 759-774.
[21] OCHALSKI ME, ORWIG KE.Thalidomide reduces ovarian microvasculature and protects ovarian follicles from chemotherapy damage[J]. Fertility & Sterility, 2011, 96(3): S33.

沙利度胺片致β地中海贫血患者继发性闭经1例分析

One case of secondary amenorrhea caused by thalidomide tablets in a β-thalassemia patient

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孟康康, 夏玉坤. 昂丹司琼制剂安全性风险分析[J]. 中国药物警戒, 2024, 21(9): 1034-1038.
[2]	吴凡, 付林杰, 祝赫, 徐梦艳. 基于美国FAERS和日本JADER数据库的内皮素受体拮抗剂不良事件信号分析[J]. 中国药物警戒, 2024, 21(9): 1056-1063.
[3]	卢靖, 喻珊珊, 童菲, 林卓慧, 宋路瑶. 达格列净片致严重便秘1例分析[J]. 中国药物警戒, 2024, 21(9): 1071-1074.
[4]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[5]	张凯华, 刘丁维, 付长海, 孙雪林, 闵先军. 罗沙司他联合当归补血汤对AR和NR3C2基因表达的影响[J]. 中国药物警戒, 2024, 21(8): 871-877.
[6]	魏芬芳, 吴文宇, 李丽敏, 唐碧雨, 吴建茹. 国外药品获益-风险评价方法概述与启示[J]. 中国药物警戒, 2024, 21(8): 900-905.
[7]	王玉玺, 张宗林, 王颖丽, 陈亚飞, 李俊生, 霍艳飞, 谢彦军, 刘文启. 560例脉络舒通丸不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 921-924.
[8]	赵俊, 董丽, 王洋, 梁瑜, 杨雪, 李恩泽. 艾司洛尔不良反应/事件报告分析[J]. 中国药物警戒, 2024, 21(8): 925-930.
[9]	张乾, 恽渊, 何恋. 1例利培酮致高泌乳素血症患者的药学监护[J]. 中国药物警戒, 2024, 21(8): 936-938.
[10]	晁滢, 张学梅, 张成健, 王贝. 注射用头孢曲松钠致儿童输尿管结石及胆囊结石1例分析[J]. 中国药物警戒, 2024, 21(8): 943-945.
[11]	郭海嬿, 何波, 闫鸿丽, 杨雪婷. 稳心颗粒致持续性呃逆1例分析[J]. 中国药物警戒, 2024, 21(8): 946-948.
[12]	王丹, 董铎, 田春华. 我国药物警戒制度发展历程和思考[J]. 中国药物警戒, 2024, 21(7): 735-740.
[13]	邵波, 郭晓昕. 中药药物警戒回顾与思考[J]. 中国药物警戒, 2024, 21(7): 741-745.
[14]	阿拉腾花, 王振兴, 张晓朦, 世伟, 席成伟, 王聪慧, 王立群, 张冰. 基于药品不良反应监测数据的心脏器官伤害风险信号挖掘分析[J]. 中国药物警戒, 2024, 21(7): 752-758.
[15]	程毅菁, 李涛, 刘军廷, 黄贵民, 钟旭丽, 林爱华, 潘守东, 李龙, 白东升, 占小俊, 刘振江, 任韡, 邰隽. 基于真实世界数据的注射用尖吻蝮蛇血凝酶儿童用药安全性评价[J]. 中国药物警戒, 2024, 21(7): 787-790.